Startups
Precision AQ empowers pharma and biotech leaders to streamline access to life-changing medicines through data integration, strategic expertise, and innovative solutions across the commercialization journey.
Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 27, 2025 | Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies | Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, ... |
| Dec 10, 2024 | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drugNo c... |
| Dec 10, 2024 | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug No ... |
| Nov 14, 2024 | AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease | AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher t... |
| Nov 13, 2024 | AC Immune to Present at the Jefferies 2024 London Healthcare Conference | AC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative d... |
| Nov 11, 2024 | Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses | Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses Mon, Nov 11, 2024 08:49 CET Report this content Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy a... |
| Oct 10, 2024 | Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients | Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients Thu, Oct 10, 2024 11:09 CET Report this content Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative... |
| Oct 8, 2024 | Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer | PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor One of two EGFR programs being developed with Scorpion Therapeutics CASTRES, France and BOS... |
| Oct 2, 2024 | Pfizer's Strategic Shift: Selling Haleon Shares and Precision Medicine's New Leadership | In the ever-evolving landscape of pharmaceuticals, companies often pivot to stay ahead. Pfizer is making waves again. The pharmaceutical giant has announced a significant move: selling its stake in Haleon, the maker of Sensodyne, for a stag... |
Show more
Reviews 0
FAQ about Precision AQ
What has the press written about Precision AQ?
Parsers VC has collected 15 articles mentioning Precision AQ, among them “Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies” (May 27, 2025) and “AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome” (Dec 10, 2024).
Is Precision AQ still active?
Yes, Precision AQ is active; its latest activity on Parsers VC dates from Dec 3, 2025.